Prospective observational study on the efficacy and safety of EPA in advanced gastric cancer patients treated by S-1+CDDP as first line. - Prospective observational study on the efficacy and safety of EPA in advanced gastric cancer patients treated by S-1+CDDP as first line.

Kyushu medical center, medical oncology0 个研究点目标入组 30 人开始时间: 2015年1月15日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Patients with active bleeding or beedingtendency (2)Patients who receive anticoagulant or antiplatelet drug (3)Patients without prior therapy with drugs or supplements contained icosapentaenoic acid (4)Patients with a history of allergy to icosapentaenoic acid (5)Patients scheduled for surgery (6)Patients scheduled for immune therapy (7)Patients with serious complication (8)Patients with immune-mediated illness (9)Patients with digestive symptom by ileus or gastrointestinal bleeding (10)Patients with symptomatic brain metastases or carcinomatous meningitis (11)Patients with massive pericardial effusion, pleural effusion or ascites *except for patients if effusions and ascites did not accumulate for more than two weeks after dranage therapy *include patients if pleurosclerosis was performed with anticancer drugs except OK-432 (12)Metachronous and synchronous double cancer (13)Bood tests positive for HBs antigen (14)Patients who receive continuous corticosteroid administration (15)Patients who receive drugs interact with S-1 or cisplatin (16)Uncontrolled psychiatry disease (17)Pregnant or lactating female and men who want to get partner pregnant (18)Judged inappropriate by the investigators

发起方

Kyushu medical center, medical oncology